Place of anti-IL6R in the therapeutic strategy in NMOSD-AQP4+, MOGAD, and NMOSD double-seronegative patients

医学 多发性硬化 疾病 重症监护医学 梅德林 治疗方法 物理疗法 纳塔利祖玛 临床试验 抗体疗法 自身免疫性疾病 退行性疾病
作者
Chloé Comet,Guillaume Jouvenot,Bertrand Bourre,Jonathan Ciron,Bertrand Audoin,Xavier Ayrignac,Mikaël Cohen,Romain Deschamps,Françoise Durand‐Dubief,Élisabeth Maillart,Caroline Papeix,Hélène Zéphir,Romain Marignier,Aurélie Ruet,Laure Michel,Éric Thouvenot,Nicolas Collongues,for the NOMADMUS Study Group
出处
期刊:Multiple Sclerosis Journal [SAGE Publishing]
卷期号:32 (2): 214-223 被引量:1
标识
DOI:10.1177/13524585251396421
摘要

Background: Anti-interleukin-6 receptor (anti-IL6R) therapy has demonstrated efficacy in AQP4 + NMOSD, and emerging evidence suggests a similar benefit in patients with MOGAD. Objectives: This study aimed to evaluate the role of anti-IL6R therapy within the treatment algorithm for both NMOSD and MOGAD. In addition, it investigated whether CSF-IL6 levels could serve as a predictive biomarker for treatment response. Methods: Patients with NMOSD or MOGAD who had received at least one dose of anti-IL6R therapy were identified from the NOMADMUS registry. Relapse incidence and timing were analyzed relative to treatment periods. Survival analyses and correlation assessments were conducted between CSF-IL6 concentrations and relapse occurrence. Results: Among 51 patients, anti-IL6R therapy was mostly employed as a second-line treatment in 51% of cases, with 62.7% of patients having previously received rituximab. Anti-IL6R therapy significantly reduced annualized relapse rate, which was lower during anti-IL6R exposure periods than at 1-year pre-exposure periods for AQP4 + ( n = 25, p = 0.007) and MOGAD ( n = 15, p = 0.003) patients, without a significant effect on EDSS scores. No correlation between CSF-IL6 levels and relapse rates was observed, despite higher CSF-IL6 levels in MOGAD. Conclusions: Anti-IL6R therapy appears effective in reducing disease activity in both NMOSD and MOGAD, particularly in patients previously unresponsive to rituximab.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
舒适飞薇完成签到,获得积分20
刚刚
斯文网络完成签到,获得积分10
刚刚
天真芷天发布了新的文献求助10
刚刚
标致土豆发布了新的文献求助10
刚刚
万能图书馆的应助被小王采纳,获得10
刚刚
崔伟完成签到,获得积分10
刚刚
嘻嘻哈哈的应助被gaoyingxin采纳,获得10
1秒前
1秒前
1秒前
Zz完成签到,获得积分10
1秒前
在水一方的应助被科研通管家采纳,获得10
1秒前
852的应助被xu采纳,获得10
1秒前
123发布了新的文献求助10
1秒前
传奇3的应助被科研通管家采纳,获得10
2秒前
慕青的应助被科研通管家采纳,获得10
2秒前
所所的应助被科研通管家采纳,获得10
2秒前
爆米花的应助被科研通管家采纳,获得10
2秒前
天天向上的应助被科研通管家采纳,获得10
2秒前
桐桐的应助被科研通管家采纳,获得10
2秒前
Maestro_S的应助被科研通管家采纳,获得10
2秒前
2秒前
充电宝的应助被科研通管家采纳,获得10
3秒前
无极微光的应助被科研通管家采纳,获得20
3秒前
CodeCraft的应助被科研通管家采纳,获得10
3秒前
orixero的应助被科研通管家采纳,获得10
3秒前
斯文网络发布了新的文献求助10
3秒前
3秒前
3秒前
Maestro_S的应助被科研通管家采纳,获得10
3秒前
Owen的应助被科研通管家采纳,获得10
3秒前
3秒前
PIUPIU1003的应助被科研通管家采纳,获得10
4秒前
FashionBoy的应助被科研通管家采纳,获得10
4秒前
科研通AI2S的应助被junge采纳,获得10
4秒前
共享精神的应助被科研通管家采纳,获得10
4秒前
英俊的铭的应助被科研通管家采纳,获得10
4秒前
阿申爱乐的应助被科研通管家采纳,获得30
4秒前
实验室女巫完成签到,获得积分10
4秒前
充电宝的应助被科研通管家采纳,获得10
4秒前
Orange的应助被科研通管家采纳,获得10
4秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8186261
求助须知:如何正确求助?哪些是违规求助? 9574697
关于积分的说明 21837731
捐赠科研通 7783915
什么是DOI,文献DOI怎么找? 3434752
关于科研通互助平台的介绍 2559109
邀请新用户注册赠送积分活动 2481528